Studied in registered human trials with published pharmacokinetic data, but not approved. Dosing outside a trial protocol has no established safety margin.
Disappearance half-time 4.3 +/- 1.4 minutes after IV administration in normal men, with metabolic clearance 39.7 mL/kg/min. The frequently quoted "11-12 minutes" appears only in secondary sources; the measured primary value is ~4.3 min IV. No validated subcutaneous half-life was located. Intranasal bioavailability is only 3-5%.
Model a dosing schedule →Weight-based, not fixed-mcg. In healthy men the minimal effective IV dose was 0.25 mcg/kg with maximal GH release at 1-2 mcg/kg IV. Absolute values left blank rather than back-calculated from an assumed body weight.
Historically the most common adverse event was injection-site reaction. Because sermorelin acts on the pituitary via the GHRH receptor, GH release remains subject to negative feedback and somatostatin tone, which limits supraphysiologic exposure relative to exogenous rhGH. Requires an intact pituitary to work at all. Marketed anti-ageing use is off-label and unsupported by the approved indication.